PTC THERAPEUTICS, INC. (PTCT) earnings date
Feb 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-20
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Oct 29, 2026 | after close | 29 | 8-K |
| Q2 FY2026 | Thu, Jul 30, 2026 | after close | 30 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 19, 2026 | after close | 50 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | after close | 35 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Tue, May 6, 2025 | after close | 36 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | after close | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "EX-99.1 2 tmb-ex99d1.htm EX-99.1 Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results – Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue guidance raised to $960 to $990 million – – Sephience™ (sepiapterin) Q3 2026 revenue of $182 million, with continued growth in the US and ongoing global expansion – – Acquired ST-920 Fabry disease gene therapy; BLA submission expected" exhibit |
| Q3 FY2026 | "With a strong patient base, the large global market, and the reports of meaningful treatment benefits, we look forward to continued growth both in the US and internationally.” Key Corporate Updates · Q3 2026 total revenue of $358 million, including $276 million of product revenue · Sephience launch momentum continues with steady growth in the US and ongoing global expansion o Q3 2026 revenue of $182 million, including $145 million revenue in the US and $37 million revenue ex-US, up over 20% from Q2 2026 o Over 2,000 active patients worldwide as of September 30, 2026 · ST-920 Fabry disease BL" exhibit |
| Q3 FY2026 | "Acquired in-process research and development expense was $111.0 million for the third quarter of 2026 and related to the purchase of the ST-920 program. · Cash, cash equivalents, and marketable securities were $2,127.9 million on September 30, 2026, compared to $1,945.4 million on December 31, 2025. · Shares issued and outstanding as of September 30, 2026, were 83,535,767. PTC Updates Full-Year 2026 Financial Guidance · Expected total revenue increased to $1.29 to $1.32 billion, with total product revenue guidance raised to $960 to $990 million from $850 to $950 million · GAAP R&D and SG&A e" exhibit |
| Q2 FY2026 | "EX-99.1 2 tmb-20260728xex99d1.htm EX-99.1 Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million – – Sephience™ (sepiapterin) Q2 2026 revenue of $151 million , with continued broad uptake and geographical expansion – – Strong cash position of $2.2 billion as of June 30, 2026 – WARR" exhibit |
| Q2 FY2026 | "Vatiquinone PROVE-FA study to support NDA resubmission for treatment of Friedreich’s ataxia expected to initiate in Q3 2026 o Global study will enroll approximately 120 individuals with Friedreich’s ataxia age 7 to 21 o Study includes open-label treatment arm with matched natural history control group" exhibit |
| Q2 FY2026 | "PTC pipeline continues to advance o PTC303 named as MSH3 splicing program development candidate targeting Huntington’s disease and myotonic dystrophy with plan to enter clinic in 2027 o Phase 1 study of PTC612, an oral NLRP3 inhibitor, initiated in Q2 2026 o Phase 2a study of PTC844, a next-generation DHODH inhibitor, expected to initiate in Q3 2026" exhibit |
| Q2 FY2026 | "Shares issued and outstanding as of June 30, 2026, were 83,327,286. PTC Updates Full-Year 2026 Financial Guidance" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/PTCT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/PTCT
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/PTCT/"><img src="https://veritasdata.dev/embed/PTCT.svg" alt="PTCT earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/PTCT/)
Script
<script async src="https://veritasdata.dev/embed/PTCT.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/PTCT"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.